Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report

Digestive and Liver Disease

Volumn 35, Issue 7, 2003, Pages 503-506

  Vaccaro, Francesco ^a   Giorgi, A ^a   Riggio, O ^a   De Santis, A ^a   Laviano, A ^a   Rossi Fanelli, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Ascites; Hepato renal syndrome; Liver cirrhosis; Spontaneous bacterial peritonitis; Terlipressin

Indexed keywords

ALBUMIN; CEFOTAXIME; FUROSEMIDE; SPIRONOLACTONE; TERLIPRESSIN; VASOPRESSIN DERIVATIVE; DRUG DERIVATIVE; LYPRESSIN; SERUM ALBUMIN; VASOCONSTRICTOR AGENT;

ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; AGED; ANTIBIOTIC THERAPY; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BOLUS INJECTION; CASE REPORT; DISEASE SEVERITY; DOSE RESPONSE; DRUG WITHDRAWAL; ECHOGRAPHY; HEPATORENAL SYNDROME; HEPATOSPLENOMEGALY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; ISCHEMIA; ISCHEMIC COLITIS; KIDNEY FAILURE; LABORATORY TEST; LIVER CIRRHOSIS; LOW DRUG DOSE; MALE; RECTUM HEMORRHAGE; RISK ASSESSMENT; RISK FACTOR; SKIN TOXICITY; URINE FLOW RATE; BACTERIAL INFECTION; CHEMICALLY INDUCED DISORDER; FATALITY; GASTROINTESTINAL HEMORRHAGE; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY; PERITONITIS; RECTUM;

AGED; ASCITES; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATAL OUTCOME; GASTROINTESTINAL HEMORRHAGE; HEPATORENAL SYNDROME; HUMANS; INFUSIONS, INTRAVENOUS; ISCHEMIA; LIVER CIRRHOSIS; LYSINE VASOPRESSIN; MALE; PERITONITIS; RECTUM; SERUM ALBUMIN; VASOCONSTRICTOR AGENTS;

EID: 0242336621     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00225-1     Document Type: Article

References (28)

1. Gines A, Escorsell A, Gines P, Salò P, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-36.
2. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of the refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-76.
3. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen J, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
4. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41.
5. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine. Hepatology 1999;30:870-5.
6. Fachinformation: Glycylpressin R. Terlipressin Acetate. Kiel: Ferring Arzneimittel GmbH; 1996.
7. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-70.
8. Ganne-Carrie N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig Dis Sci 1996;41:1054-6.
9. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-8.
10. Bonnard PH, Bernard B, Halimi CH, Mathurin PH, Demontis R, di Martino V, et al. Effect of terlipressin on hepatorenal syndrome in cirrhotic patients: results of a pilot study (abstract). Gastroenterology 1998;114:A1214.
11. Duhamel C, Maullion J, Berkelmans I, Bourienne A, Tranvouez JL. Hepatorenal syndrome in cirrhotic patients: terlipressin is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? Am J Gastroenterol 2000;95:2984-5.
12. Cervoni JP, Lecomte T, Collier C, Auroux J, Simon C, Landi B, et al. Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis. Am J Gastroenterol 1997;92:2113-4.
13. Arroyo V, Jiménez W. Complication of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000;32(Suppl. 1):157-70.
14. Bories PN, Campillo B, Azaou L, Scherman E. Long-lasting NO overproduction in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1997;25:1328-33.
15. Jimenez W, Ros J, Morales-Ruiz M, Navasa M, Solè M, Colmenero J, et al. Nitric oxide production and inducible nitric oxide synthase expression in peritoneal macrophages of cirrhotic patients. Hepatology 1999;30:670-6.
16. Navasa M, Follo A, Filella X, Jimenez W, Francitorra A, Planas R, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998;27:1227-32.
17. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. New Engl J Med 1999;341:403-9.
18. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994;269:13725-8.
19. Vodovotz Y, Kwon NS, Pospichil M, Manning J, Paik J, Nathan C. Inactivation of nitric oxide synthase after prolonged incubation of mouse macrophages with interferon gamma and bacterial lipopolysaccharide. J Immunol 1994;152:4110-8.
20. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-42.
21. Meyer J, Booke M, Waurick R, Prien T, Van Aken H. Nitric oxide synthase inhibition restores vasopressor effects of norepinephrine in ovine hyperdynamic sepsis. Anesth Analg 1996;83:1009-13.
22. Thiemermann C, Szabo C, Mitchell JA, Vane JR. Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci USA 1993;90:267-71.
23. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet JC. Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 1990;259:H1038-43.
24. Scharte M, Meyer J, Van Aken H, Bone H-G. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 2001;29:1756-60.
25. Tetsuka T, Ando Y, Asano Y. Arginine vasopressin inhibits interleukin-1[beta]-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. J Hypertens 1997;15:627-32.
26. Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-82.
27. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7.
28. Salerno F, Angeli P, Bernardi M, Laffi G, Riggio O, Salvagnini M. Clinical practice guidelines for the management of cirrhotic patients with ascites. Committee on Ascites of Italian Association for the Study of the Liver. Ital J Gastroenterol Hepatol 1999;31:626-34.